Poisons and Narcotic Drugs (Amendment) Act 1986 (ACT)
AUSTRALIAN CAPITAL TERRITORY
Poisons and Narcotic Drugs (Amendment) Ordinance 1986
No. 32 of 1986
I, THE ADMINISTRATOR of the Government of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910.
Dated 24 July 1986.
J. A. ROWLAND
Administrator
By His Excellency’s Command,
G. SCHOLES
Minister of State for Territories
An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978
Short title
1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1986.1
Principal Ordinance
2. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2
Schedules 1 to 8 (inclusive)
3. Schedules 1 to 8 (inclusive) to the Principal Ordinance are repealed and the Schedules set out in the Schedule to this Ordinance are substituted.
Schedule 12
4. Schedule 12 to the Principal Ordinance is amended—
(a)by inserting—
“Acetorphine”
before—
“4-Bromo-2,5-dimethoxyamphetamine”;
(b)by inserting—
“N-Ethyl-1-phencyclohexylamine
Etorphine”
after—
“4,5-Ethylenedioxy-3-methoxyamphetamine”;
(c)by inserting—
“1-(1-Phencyclohexyl) pyrrolidine”
after—
“3,4-Methylenedioxyamphetamine”;
(d)by inserting—
“Harmaline
Harmine”
after—
“4,5-Ethylenedioxy-3-methoxyamphetamine”; and
(e)by inserting—
“1-(1-(2-Thienyl) cyclohexyl) piperidine”
after—
“2,3,4,5-Tetramethoxyamphetamine”.
Schedule 13
5. Schedule 13 to the Principal Ordinance is amended—
(a)by omitting—
“Electrical components, including electric lamps
Explosives”
and substituting—
“Electrical accumulators and batteries
Electrical components, including electric lamps
Electronic components
Explosives
Food”;
(b)by omitting—
“Matches”
and substituting—
“Lubricants, unless specified in any other Schedule
Matches
Motor fuels, other than those containing methyl alcohol, unless specified in any other Schedule”; and
(c)by inserting—
“Printing inks and ink additives except when containing a pesticide
Single-use tubes for the estimation of alcohol content of breath”
after—
“Photographic paper and film”.
SCHEDULE Section 3
SCHEDULES TO BE SUBSTITUTED FOR
SCHEDULES 1 TO 8 (INCLUSIVE) TO PRINCIPAL ORDINANCE
SCHEDULE 1 Section 3
Aconite (root of Aconitum napellus)
Antimony, compounds of, except:
(a)antimony chloride in polishes; or
(b)when included in Schedule 4.
Atropine except when included in Schedule 2 or 4.
Belladonna Herb except when included in Schedule 2.
Bromine (excluding its salts and derivatives).
Brucine except when used in concentrations of 0.02 per cent or less for the denaturation of alcohol.
Comfrey (Symphytum) being any part of the dried plant, its extracts and preparations, for human internal use.
Coniine
Cotarnine
Croton Oil
Cyanides—see Hydrocyanic Acid.
Homatropine except when included in Schedule 2.
Hydrocyanic Acid and Cyanides in preparations for therapeutic use except when included in Schedule 2.
Hyoscine except when included in Schedule 2 or 4.
Hyoscyamine except when included in Schedule 2.
Hyoscyamus except when included in Schedule 2.
Lobelia except:
(a)in preparations for smoking or burning; or
(b)when included in Schedule 2.
Mercuric Chloride except when included in Schedule 2 or 7.
Mercuric Iodide except when included in Schedule 2 or 6.
Mercuric Nitrate except when included in Schedule 2.
Mercuric-potassium Iodide except when included in Schedule 2.
Mercuric Thiocyanate except when included in Schedule 6.
Mercury, organic compounds of, except:
(a)when included in Schedule 2, 4 or 6;
(b)ethoxyethyl mercury chloride and ethyl mercury chloride in Schedule 7; or
(c)in preparations containing 0.01 per cent or less of mercury as a preservative.
Nux Vomica
Phosphorus Yellow (excluding its salts and derivatives) except when included in Schedule 6.
Savin, oil of.
Stramonium except:
(a)in preparations for smoking or burning; or
(b)when included in Schedule 2.
Tansy, oil of.
Veratrum, except for therapeutic use.
SCHEDULE 2 Section 3
Acetic Acid (excluding its salts and its derivatives) for therapeutic use in preparations containing more than 80 per cent of acetic acid.
Acetyldihydrocodeine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of acetyldihydrocodeine.
Aloxiprin
Ammoniated Mercury
Antazoline in eye drops.
Aspirin and its preparations and derivatives except:
(a)tablets or capsules each containing 325 milligrams or less of aspirin as the only therapeutically active constituent when:
(i)the pack is labelled with the warning statement:
WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD: or
CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii)packed in blister or strip packaging or in containers with a child-resistant closure; and
(iii)in a primary pack containing not more than 25 such tablets or capsules; or
(b)in individually wrapped powders or sachets of granules each containing 650 milligrams or less of aspirin as the only therapeutically active constituent when:
(i)the pack is labelled with the warning statement:
WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD: or
CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii)in a primary pack containing not more than 12 such powders or sachets of granules; or
(c)when included in Schedule 4.
Atropine, except when included in Schedule 4:
(a)in preparations containing 0.25 per cent or less of atropine;
(b)atropine sulphate, 0.6 mg tablets in packs of six, when labeled for treatment of organophosphorus poisoning.
Belladonna Herb in preparations containing 0.25 per cent or less of the alkaloids of belladonna, calculated as hyoscyamine.
Benzamine when included in:
(a)lozenges, pastilles, tablets and capsules containing 30 mg or less of benzamine in each;
(b)suppositories or bougies containing 200 mg or less of benzamine in each;
(c)preparation for external use, other than eye drops, containing 10 per cent or less of benzamine.
Benzocaine when included in:
(a)lozenges, pastilles, tablets and capsules containing 30 mg or less of benzocaine in each;
(b)suppositories or bougies containing 200 mg or less of benzocaine in each;
(c)preparations for external use, other than eye drops, containing 10 per cent or less of benzocaine.
Benzoyl Peroxide in preparations for external human therapeutic use containing 5 per cent or less of benzoyl peroxide.
Bromhexine
Brompheniramine when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Buclizine in primary packs of 10 doses or less, for the prevention or treatment of motion sickness.
Bufexamac in preparations containing 5 per cent or less of bufexamac for external human therapeutic use, and in suppositories.
Butylaminobenzoate when included in:
(a)lozenges, pastilles, tablets, and capsules containing 30 mg or less of butylaminobenzoate in each;
(b)suppositories or bougies containing 200 mg or less of butylaminobenzoate in each;
(c)preparations for external use, other than eye drops, containing 10 per cent or less of butylaminobenzoate.
Carbaryl in preparations for external human therapeutic use containing 2 per cent or less of carbaryl.
Carbenoxolone for topical oral use.
Carbetapentane except in preparations containing 0.5 per cent or less of carbetapentane.
Chloroform (excluding its derivatives) for therapeutic use except:
(a)in preparations containing 10 per cent or less of chloroform where the chloroform content is declared on the label; or
(b)when included in Schedule 4.
Chlorpheniramine when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Cinnamedrine
Clioquinol and other halogenated derivatives of 8-Hydroxyquinoline for external human use.
Codeine:
(a)when compounded with aspirin, paracetamol or salicylamide or any one of their derivatives, in tablets or capsules each containing 10 mg or less of codeine, and no other analgesic substance, when:
(i)packed in blister or strip packaging or in containers with child-resistant closures; and
(ii)in a primary pack containing 25 or less dosage units; or
(b)when compounded with one or more other therapeutically active substances:
(i)in divided preparations containing 10mg or less of codeine per dosage unit; or
(ii)in undivided preparations containing 0.25 per cent or less of codeine.
Creosote, for therapeutic use, except in preparations containing 3 per cent or less of phenols included in Schedule 2.
Cyanides—see Hydrocyanic Acid.
Dexchlorpheniramine when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Dextromethorphan in preparations containing 1 per cent or less of dextromethorphan when compounded with one or more other medicaments in such a way that the dextromethorphan contained therein cannot readily be extracted.
Dextrorphan in preparations containing 1 per cent or less of dextrorphan.
Dicophane (DDT) in preparations for human therapeutic use.
Dicyclomine in preparations containing 0.1 per cent or less of dicyclomine.
Dihydrocodeine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of dihydrocodeine.
Dimenhydrinate in primary packs of 10 doses or less, for the prevention or treatment of motion sickness.
Dimethisoquin in preparations for topical use.
Diphemanil Methylsulphate in preparations for topical use.
Diphenhydramine:
(a)in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b)when compounded with one or more of the following medicaments:
(i)an antitussive except codeine or dihydrocodeine;
(ii)an expectorant; or
(iii)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Diphenylpyraline when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Doxylamine when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Ephedrine except:
(a)when included in Schedule 3;
(b)when compounded with one or more other medicaments in liquid preparations containing 10mg or less of ephedrine per recommended dose; or
(c)in preparations for topical use containing 1 per cent or less of ephedrine.
Erythrityl Tetranitrate for therapeutic use.
Etafedrine
Ether for therapeutic use except:
(a)in preparations containing 10 per cent or less of ether; or
(b)when included in Schedule 4.
Ethoheptazine in preparations containing 1 per cent or less of ethoheptazine.
Ethylmorphine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of ethylmorphine.
Fluorides
(a)in sodium fluoride in preparations for human ingestion containing 2.2 mg or less of sodium fluoride per dosage unit;
(b)in other metallic fluoride substances, including ammonium fluoride when intended for therapeutic purposes, except:
(i)in dentifrices containing 1000 mg/kg or less of fluoride ion; or
(ii)in substances containing 15 mg/kg or less of fluoride ion.
Gelsemium
Glutaraldehyde for human therapeutic use.
Glyceryl Trinitrate for therapeutic use except when included in Schedule 4.
Guaiphenesin
(a)in liquid preparations containing 2 per cent (200 mg/10 ml) or less of guaiphenesin; or
(b)in divided preparations containing 120 mg or less of guaiphenesin in each dosage unit.
Hexachlorophane in preparations for human skin cleansing purposes containing 3 per cent or less of hexachlorophane except in preparations for use on infants as specified in Schedule 4.
Homatropine in preparations containing 0.25 per cent or less of homatropine.
Human Chorionic Gonadotrophin or antibody in pregnancy test kits.
Hydrocyanic Acid and Cyanides in preparations for therapeutic use containing the equivalent of 0.15 per cent or less of hydrocyanic acid.
8-Hydroxyquinoline and its non-halogenated derivatives, for human therapeutic use, except in preparations for external use containing 1 per cent or less of such substances.
Hyoscine, except when included in Schedule 4, in preparations containing 0.25 per cent or less of hyoscine.
Hyoscyamine in preparations containing 0.25 per cent or less of hyoscyamine.
Hyoscyamus in preparations containing 0.25 per cent or less of the alkaloids of hyoscyamus calculated as hyoscyamine.
Iodine (excluding its salts, derivatives and iodophors), in preparations for human therapeutic use containing more than 2.5 per cent of available iodine.
Iron Compounds for human internal use except:
(a)when included in Schedule 4;
(b)in divided preparations containing 5 mg or less of iron per unit dose; or
(c)in liquid oral preparations containing 0.1 per cent or less of iron.
Isopropamide in preparations containing 2 per cent or less of isopropamide for cutaneous use.
Isosorbide Dinitrate for therapeutic use.
Lignocaine when included in:
(a)lozenges, pastilles, tablets and capsules containing 30 mg or less of lignocaine in each;
(b)suppositories or bougies containing 200 mg or less of lignocaine in each;
(c)preparations for external use, other than eye drops, containing 10 per cent or less of lignocaine.
Lindane in preparations for external human therapeutic use containing 2 per cent or less of lindane.
Lobelia in preparations containing 0.5 per cent or less of the alkaloids of lobelia, except preparations for smoking or burning.
Maldison in preparations for external human therapeutic use containing 2 per cent or less of maldison.
Mebendazole for human therapeutic use.
Mercuric Chloride in preparations containing 0.5 per cent or less of mercuric chloride, except when included in Schedule 7.
Mercuric Iodide in preparations for therapeutic use containing 2 per cent or less of mercuric iodide.
Mercuric Nitrate in preparations containing the equivalent of 3 per cent or less of mercury (Hg), in such form.
Mercuric Oxide and all oxides of mercury.
Mercuric-potassium Iodide in preparations containing the equivalent of 2 per cent or less of mercuric iodide, in such form.
Mercury (Metallic) for therapeutic use.
Mercury, organic compounds of, for topical therapeutic use in preparations containing 0.5 per cent or less of mercury.
Methoxamine except:
(a)preparations containing 0.5 per cent or less of methoxamine;
(b)preparations for external use containing 1 per cent or less of methoxamine.
Methoxyphenamine
Methylephedrine
Naphazoline
Niclosamide for human therapeutic use.
Nicocodine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of nicocodine.
Nicodicodine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of nicodicodine.
Nitric Esters of polyhydric alcohols for therapeutic use.
Norcodeine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of norcodeine.
Noscapine
Oxethazaine in preparations for internal use only.
Oxolamine
Oxymetazoline
Papaverine
Paracetamol and its preparations and derivatives except:
(a)tablets or capsules each containing 500 milligrams or less of paracetamol as the only therapeutically active constituent when:
(i)the pack is labelled with the warning statement:
WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD: or
CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii)packed in blister or strip packaging or in containers with a child-resistant closure; and
(iii)in a primary pack containing not more than 25 such tablets or capsules; or
(b)in individually wrapped powders or sachets of granules each containing 1000 milligrams or less of paracetamol as the only therapeutically active constituent when:
(i)the pack is labelled with the warning statement:
WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii)in a primary pack containing not more than 12 such powders or sachets of granules; or
(c)when included in Schedule 4.
Phedrazine
Phenamazoline
Phenazone for external use.
Pheniramine
(a)in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b)when compounded with one or more of the following medicaments:
(i)an antitussive except codeine or dihydrocodeine;
(ii)an expectorant; or
(iii) a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Phenol and any homologue of phenol boiling below 220º C, for therapeutic use, except in preparations containing 3 per cent or less by weight of such substances.
Phenylenediamines and alkylated phenylenediamines for therapeutic use.
Phenylephrine except:
(a)preparations containing 0.5 per cent or less of phenylephrine; or
(b)preparations for external use containing 1 per cent or less of phenylephrine.
Pholcodine when compounded with one or more other medicaments, in preparations containing 1 per cent or less of pholcodine.
Podophyllum Resin (Podophyllin) for external human use in preparations containing 10 per cent or less of podophyllin.
Potassium Chlorate for therapeutic use except in preparations containing 10 per cent or less of potassium chlorate.
Pramoxine when included in preparations for external use, other than eye drops, containing 1 per cent or less of pramoxine.
Procyclidine in preparations containing 5 per cent or less of procyclidine for cutaneous use.
Promethazine
(a)in primary packs of 10 doses or less, for the prevention or treatment of motion sickness; or
(b)when compounded with one or more of the following medicaments:
(i)an antitussive except codeine or dihydrocodeine;
(ii)an expectorant; or
(iii)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Propantheline in preparations for topical use.
Propoxur in preparations for external human therapeutic use containing 0.2 per cent or less or propoxur.
Propylhexedrine in appliances for inhalation in which the substance is absorbed upon an inert solid material.
Propyphenazone
Pseudoephedrine
(a)in divided preparations containing 60 mg or less of pseudoephedrine per dosage unit; or
(b)in liquid preparations containing 60 mg or less per recommended adult dose.
Pyrantel for human therapeutic use.
Pyrithione Zinc for human therapeutic use, except in preparations containing 2 per cent or less of pyrithione zinc, when:
(a)in semisolid hair preparations; or
(b)in shampoos labeled with either of the statements “keep out of eyes” or “if in eyes, rinse well with water”.
Salicylamide and its preparations and derivatives except:
(a)tablets or capsules each containing 500 milligrams or less of salicylamide as the only therapeutically active constituent when:
(i)the pack is labelled with the warning statement:
WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii)packed in blister or strip packaging or in containers with a child-resistant closure; and
(iii)in a primary pack containing not more than 25 such tablets or capsules; or
(b)in individually wrapped powders or sachets of granules each containing 1,000 milligrams or less of salicylamide as the only therapeutically active constituent when:
(i)the pack is labelled with the warning statement:
WARNING—THIS MEDICATION MAY BE DANGEROUS WHEN USED IN LARGE AMOUNTS OR FOR A LONG PERIOD; or
CAUTION—THIS PREPARATION IS FOR THE RELIEF OF MINOR AND TEMPORARY AILMENTS AND SHOULD BE USED STRICTLY AS DIRECTED. PROLONGED USE WITHOUT MEDICAL SUPERVISION COULD BE HARMFUL; and
(ii)in a primary pack containing not more than 12 such powders or sachets of granules; or
(c)when included in Schedule 4.
Silver Nitrate for therapeutic use
Sodium Nitrate for therapeutic use.
Staphisagria except in preparations containing 0.2 per cent or less of staphisagria.
Stramonium in preparations containing 0.25 per cent or less of the alkaloids calculated as hyoscyamine, except preparations for smoking or burning.
Tetrahydrozoline
Thenyldiamine
(a)in nasal preparations for topical use; or
(b)when compounded with one or more of the following medicaments;
(i)an antitussive except codeine or dihydrocodeine;
(ii)an expectorant; or
(iii)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Tramazoline
Trimerprazine when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Trimizoline
Triprolidine when compounded with one or more of the following medicaments:
(a)an antitussive except codeine or dihydrocodeine;
(b)an expectorant; or
(c)a sympathomimetic amine;
except in preparations for the treatment of children under 2 years of age.
Tymazoline
Xylometazoline
SCHEDULE 3 Section 3
Acepifylline in liquid oral preparations.
Adrenaline in preparations containing 1 per cent or less of adrenaline except in preparations containing 0.02 per cent or less of adrenaline.
Aminophylline in liquid oral preparations.
Amyl Nitrite
Benzoyl Peroxide in preparations containing 10 per cent or less of benzoyl peroxide for external human therapeutic use, except when included in Schedule 2.
Brompheniramine in oral preparations except when included in Schedule 2.
Buclizine in oral preparations except when included in Schedule 2.
Butyl Nitrite
Chloral Hydrate for human internal therapeutic use in preparations containing 5 per cent or less of chloral hydrate, when packed in containers of 100ml or less.
Chlorofluorocarbons—see Fluorocarbons
Chlorpheniramine in oral preparations except when included in Schedule 2.
Clemastine in oral preparations.
Clotrimazole, for human use in preparations containing 1 per cent or less of clotrimazole, for treatment of fungal infections of the skin.
Codeine in capsules or tablets each containing 10mg or less of codeine when compounded with aspirin, paracetamol or salicylamide or any one of their derivatives and no other analgesic substance, except when included in Schedule 2.
Cyproheptadine in oral preparations.
Dexchlorpheniramine in oral preparations except when included in Schedule 2.
Dimenhydrinate in oral preparations except when included in Schedule 2.
Dimethindene in oral preparations.
Diphenhydramine in oral preparations except when included in Schedule 2.
Diphenylpyraline in oral preparations except when included in Schedule 2.
Dithranol for human therapeutic use.
Doxylamine in oral preparations except when included in Schedule 2.
Econazole, for human use in preparations containing 1 per cent or less of econazole, for treatment of fungal infections of the skin.
Ephedrine:
(a)when combined with no other therapeutically active ingredient;
(b)in combination with caffeine; or
(c)when compounded with one or more other therapeutically active ingredients in preparations containing more than 30 mg of ephedrine per recommended adult dose.
Fenoterol in metered aerosols delivering 200 micrograms or less of fenoterol per metered dose.
Flavoxate
Fluorocarbons and Chlorofluorocarbons alone or in combination with other propellants or refrigerants in liquefied gas form for therapeutic use.
Folic Acid for human therapeutic use except in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
Folinic Acid for human therapeutic use except in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.
Hydrocortisone and Hydrocortisone Acetate as the only therapeutically active substances in preparations for dermal use containing 0.5 per cent or less of hydrocortisone in packs containing 30 grams or less where the labelling warns against contact with the eyes of use for acne and against use on children below 2 years of age, use beyond 7 days, and use under occlusive dressings, except on medical advice.
Idoxuridine in preparations containing 0.5 per cent or less of idoxuridine for cutaneous use.
Insulin and preparations containing the specific hypoglycaemic principle of the pancreas.
Isoconazole, for human use in preparations containing 1 per cent or less of isoconazole, for treatment of fungal infections of the skin.
Mefenamic Acid in packs of 30 capsules or less when labelled for treatment of spasmodic dysmenorrhea.
Mepyramine in oral preparations.
Methdilazine in oral preparations.
Miconazole, for human use in preparations containing 2 per cent or less of miconazole, for treatment of fungal infections of the skin.
Naproxen, in packs of 12 individual dosage units, tablets or capsules, for treatment of spasmodic dysmenorrhea.
Nitrofurazone, in preparations for cutaneous use containing 0.2 per cent or less of nitrofurazone.
Octyl Nitrite
Pheniramine in oral preparations except when included in Schedule 2.
Phenylpropanolamine in preparations for relief of coughs or colds, containing 25 mg or less per dose of phenylpropanolamine.
Phenyltoloxamine in oral preparations.
Podophyllum Resin (Podophyllin) for external human use in preparations containing 20 per cent or less of podophyllin except when included in Schedule 2.
Promethazine in oral preparations except when included in Schedule 2.
Pseudoephedrine except when included in Schedule 2.
Quinine for human internal therapeutic use.
Salbutamol
(a)in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
(b)in dry powders for inhalation capsules delivering 200 micrograms or less of salbutamol per dose.
Santonin
Sodium Cromoglycate in nasal preparations, topically applied.
Terbutaline in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose.
Thenyldiamine in oral preparations except when included in Schedule 2.
Theophylline in liquid oral preparations.
Tretinoin for external human therapeutic use.
Trimeprazine
(a)in oral solid preparations; or
(b)in oral liquid preparations containing 10mg or less of trimeprazine per 5ml;
except when included in Schedule 2.
Triprolidine in oral preparations except when included in Schedule 2.
SCHEDULE 4 Section 3
Acepifylline except when included in Schedule 3.
Acetanilide and alkyl acetanilides, for human therapeutic use.
Acetazolamide
Acetohexamide
Acetylcholine and other choline esters.
Acetylcysteine
Acetyldihydrocodeine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg of acetyldihydrocodeine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of acetyldihydrocodeine;
except when included in Schedule 2.
Acetylmethyldimethyloximidophenylhydrazine
Acyclovir
Adiphenine
Adrenaline except:
(a)when included in Schedule 3; or
(b)in preparations containing 0.02 per cent or less of adrenaline.
Alcuronium
Allopurinol
Alphadolone
Alpha-receptor blocking agents not elsewhere specified in this Schedule.
Alphaxalone
Alprazolam
Alprenolol
Amantadine
Ambenonium
Ambucetamide
Ambutonium
Amethocaine
Amikacin
Amiloride
Aminocaproic Acid
Aminoglutethimide
Aminometradine
Aminophenazone and derivatives therefrom for the treatment of animals.
Aminophylline except when included in Schedule 3.
p-Aminosalicylic Acid
Aminopterin
Aminorex
Amiodarone
Amiphenazole
Amisometradine
Amitriptyline and other compounds not elsewhere specified in these Schedules structurally derived therefrom by substitution in the side chain.
Amodiaquine
Amoxycillin
Amphomycin
Amphotericin
Ampicillin
Amsacrine
Amylobarbitone when packed and labelled for injection.
Amylocaine
Anabolic steroidal agents.
Angiotensin Amide
Antazoline except when included in Schedule 2.
Antibiotics not elsewhere specified in these Schedules except—
(a)Avoparcin when intended for use as an animal feed additive;
(b)Nisin.
Antifolic Acid Substances not elsewhere specified in these Schedules.
Antihistamines except:
(a)when included in Schedule 2 or 3; or
(b)when separately specified in this Schedule.
Antimalarial Substances not elsewhere specified in these Schedules.
Antimony, organic compounds of, for therapeutic use.
Antitubercular Substances not elsewhere specified in these Schedules.
Apomorphine
Aprotinin
Arsenic—see Thiacetarsamide.
Aspirin when combined with caffeine, paracetamol or salicylamide or any derivative of these substances.
Atenolol
Atropine Methonitrate
Auranofin
Azaperone
Azapetine
Azatadine
Azlocillin
Bacitracin except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic principles;
(c)in milk replacers for calves and starter rations for pigs containing 100 mg/kg or less of antibiotic principles.
Baclofen
Bamipine
Barbituric Acid and its derivatives except when included in Schedule 8 or where separately specified.
Beclamide
Bemegride
Benactyzine and other substances structurally derived from diphenylmethane with ataractic properties when used for therapeutic purposes.
Benorylate
Benserazide
Benzamine except when included in Schedule 2.
Benzhexol
Benzilonium
Benzocaine except when included in Schedule 2.
Benzoylmetronidazole
Benzoyl Peroxide in preparations for external human therapeutic use, except when included in Schedule 2 or 3.
Benzphetamine and other substances structurally derived from beta-aminopropylbenzene or beta-aminoisopropylbenzene by substitution in the side chain or by ring closure therein (or by both substitution and closure) except:
(a)where separately specified in this or any other schedule;
(b)ephedrine and pseudoephedrine in preparations exempted from Schedule 2.
Benztropine
Benzydamine
Benzylpenicillin (including procaine penicillin) except when included in Schedule 6.
Betahistine
Beta-receptor Blocking Agents not elsewhere specified in this Schedule.
Bethanidine
Biperiden
Bismuth compounds of, for human therapeutic or cosmetic use, except:
(a)bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent w/w or less;
(b)bismuth oxychloride in cosmetics;
(c)bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.
Bleomycin
Boron compounds for human therapeutic or cosmetic use except:
(a)in dusting powders or cosmetics containing 1 per cent or less of boron;
(b)in unit dose preparations for periodontal disease containing 100 mg or less of boron.
Bretylium
Bromides, inorganic, for therapeutic use.
Bromocriptine
Bromoform for therapeutic use.
Brompheniramine except when included in Schedule 2 or 3.
Bromvaletone
Buclizine except when included in Schedule 2 or 3.
Bufexamac except when included in Schedule 2.
Bumetanide
Bupivacaine
Buprenorphine
Busulphan
Butacaine
Butylaminobenzoate except when included in Schedule 2.
Butylchloral Hydrate
Calcitonin
Calcitriol
Calcium Carbimide for therapeutic use.
Camphorated Oil excluding admixtures.
Camphotamide
Candicidin
Cantharidin
Capreomycin
Captodiame
Captopril
Capuride
Caramiphen
Carbachol
Carbamazepine
Carbaryl for human therapeutic use except when included in Schedule 2.
Carbazochrome
Carbenicillin
Carbenoxolone except when included in Schedule 2.
Carbidopa
Carbimazole
Carbocromen
Carbromal
Cardiac Glycosides not elsewhere specified in these Schedules.
Carindacillin
Carmustine
Cefaclor
Cefoperzone
Cefotaxime
Cefoxitin
Cephacetrile
Cephalexin
Cephaloridine
Cephalothin
Cephamandole
Cephapirin
Cephazolin
Cephradine
Chenodeoxycholic Acid
Chloral Formamide
Chloral Hydrate except:
(a)when included in Schedule 3;
(b)in preparations for topical use containing 2 per cent or less of chloral hydrate.
Chloramphenicol
Chlorazamil
Chlorbutol in preparations for human oral use, except in preparations containing 0.5 per cent or less of chlorbutol as a preservative.
Chlorcyclizine
Chlordiazepoxide and other substances structurally derived from benzodiazepine with ataractic properties when used for therapeutic purposes.
Chlormerodrin
Chlormethiazole
Chlormezanone
Chloroform for use in anaesthesia.
1-(4-Chlorophenoxy)-1-imidazol-l-yl-3,3-dimethyl-2- butanone for human use.
2-(4-Chlorophenyl)-1,2,4-triazole [5,la]-isoquinoline for the treatment of animals.
Chloroquine
Chlorothiazide and other substances structurally derived from benzothiadiazine for therapeutic use.
Chlorpheniramine except when included in Schedule 2 or 3.
Chlorphentermine
Chlorpromazine and other substances structurally derived from phenothiazine with ataractic properties when used for therapeutic purposes.
Chlorpropamide
Chlorprothixene
Chlortetracycline except when included in Schedule 6.
Chlorthalidone
Chlorzoxazone
Cholestyramine for human therapeutic use.
Chymopapain, injection for human therapeutic use.
Ciclacillin
Cimetidine
Cinchocaine
Cinoxacin
Cisplatin
Clanobutin, by injection for the treatment of animals.
Clavulanic Acid.
Clemastine except when included in Schedule 3.
Clemizole
Clenbuterol
Clidinium
Clindamycin
Clobazam
Clobetasone-17-butyrate
Clofenamide
Clofibrate
Clomiphene and other products specifically prepared to stimulate ovulation.
Clomipramine
Clomocycline
Clonazepam
Clonidine
Clopamide
Cloprostenol for treatment of animals.
Clorazepate
Clorexolone
Clorprenaline
Clotrimazole except when included in Schedule 3.
Cloxacillin
Clozapine
Codeine, except when included in Schedule 2 or 3, when compounded with one or more other therapeutically active substances:
(a)in divided preparations containing 30 mg or less of codeine per dosage unit; or
(b)in undivided preparations containing 1 per cent or less of codeine.
Colaspase
Colchicine
Colestipol for human therapeutic use.
Colistin
Cortisone and steroid suprarenal cortical hormones except hydrocortisone in Schedule 3.
Coumarin and phenylindanedione derivatives for therapeutic use except where separately specified in this Schedule.
Curare, Tubocurarine, d-Tubocurarine, d-Tubocurarinedimethylether, and all synthetic quaternary ammonium compounds, and other compounds having curarising properties.
Cyclandelate
Cyclizine
Cyclofenil
Cyclopentolate
Cyclopropane for therapeutic use.
Cycloserine
Cyclosporin
Cycrimine
Cyproheptadine except when included in Schedule 3.
Dacarbazine
Danazol
Dantrolene
Dapsone and all derivatives of 4,4-diaminodiphenylsulphone.
Deanol
Debrisoquine
Demecarium Bromide
Demeclocycline
Desipramine
Desmopressin
Dexchlorpheniramine except when included in Schedule 2 or 3.
Dextromethorphan except when included in Schedule 2.
Dextropropoxyphene:
(a)in oral solid dose preparations containing 135 mg or less of dextropropoxyphene per dosage unit; or
(b)in oral liquid preparations containing 2.5 per cent or less of dextropropoxyphene.
Dextrorphan except when included in Schedule 2.
Dibenzepin
Dichloralphenazone
Dichlorphenamide
Diclofenac
Dicyclomine except when included in Schedule 2.
Diethazine
Diethylcarbamazine for human therapeutic use.
Diethylpropion
Difenoxin in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulphate equivalent to at least 5 per cent of the dose of difenoxin.
Diflunisal
Digitalis and its glycosides.
Dihydralazine
Dihydrocodeine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine;
except when included in Schedule 2.
Dihydrostreptomycin except when included in Schedule 6.
Diisopropylamine Dichloroacetate
Dimenhydrinate except when included in Schedule 2 or 3.
Dimethindene except when included in Schedule 3.
Dimethisoquin except when included in Schedule 2.
Dimethoxanate
Dimethyl Sulphoxide for therapeutic use except when included in Schedule 6.
Dinitrocresols for therapeutic use.
Dinitronaphthols for therapeutic use.
Dinitrophenols for therapeutic use.
Dinitrothymols for therapeutic use.
Dinoprost for treatment of animals.
Diperodon
Diphemanil Methylsulphate except when included in Schedule 2.
Diphenhydramine except when included in Schedule 2 or 3.
Diphenidol
Diphenoxylate in preparations containing per dosage unit 2.5 mg or less of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1 per cent of the dose of diphenoxylate.
Diphenylpyraline except when included in Schedule 2 or 3.
Dipivefrin
Dipyridamole
Disophenol
Disopyramide
Disulfiram for therapeutic use.
Dithiazanine except when included in Schedule 6.
Dobutamine
Domperidone
Dopamine
Dothiepin
Doxapram
Doxepin
Doxorubicin
Doxycycline
Doxylamine except when included in Schedule 2 or 3.
Droperidol
Drostanolone
Econazole except when included in Schedule 3 or 6.
Edetic Acid for human therapeutic use in preparations for injection or infusion.
Emetine except in preparations containing 0.2 per cent or less of emetine.
Enflurane for therapeutic use.
Epicillin
Ergot
Erythromycin except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 50mg/kg or less of antibiotic principles; or
(c)in milk replacers for calves and starter rations for pigs containing 100 mg/kg or less of antibiotic principles.
Ethacrynic Acid
Ethambutol
Ethamivan
Ethchlorvynol
Ether for use in anaesthesia.
Ethinamate
Ethoglucid
Ethoheptazine except when included in Schedule 2.
Ethopropazine
Ethotoin
Ethosuximide
Ethoxzolamide
Ethyl Chloride for inhalation anaesthesia.
Ethylmorphine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;
except when included in Schedule 2.
Ethyloestrenol
Etidocaine
Etidronate
Etoposide
Etretinate
Felypressin
Fencamfamin
Fenfluramine
Fenoprofen
Fenoterol except when included in Schedule 3.
Fenpipramide
Fenpiprane
Fenprostalene for the treatment of animals.
Flavophospholipol except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic principles.
Flecainide
Flucloxacillin
Flucytosine
Flufenamic Acid
Flunisolide
Flunitrazepam
Flunixin Meglumine for the treatment of animals.
Fluorouracil and other substances structurally derived from uracil and cytotoxic properties when used for therapeutic purposes.
Fluoxumesterone
Fluprostanol for the treatment of animals.
Flurazepam
Fluroxene when specifically prepared and packed as a therapeutic agent for the induction of inhalation anaesthesia.
Fluspirilene
Follicular Stimulating Hormone (see Gonadotrophins)
Framycetin
Frusemide
Fusidic Acid
Galanthamine
Gallamine
Gentamycin
Glibornuride
Gliclazide
Glucagon
Glutethimide
Glyceryl Trinitrate in preparations for injection.
Glycopyrrolate
Glymidine
Gonadorelin
Gonadotrophins except when included in Schedule 2.
Gramicidin
Griseofulvin
Growth Hormone
Guaiphenesin except when included in Schedule 2.
Guanacline
Guanethidine
Halcinonide
Haloperidol and other substances structurally derived from butyrophenone with ataractic properties when used for therapeutic purposes.
Halothane for therapeutic use.
Heparin
Hetacillin
Hexachlorophane
(a)in preparations for use on infants;
(b)in other preparations except when included in Schedule 2 or 6.
Hexamethonium
Hexocyclium
Hydralazine
Hydroquinone for human therapeutic use except in preparations containing 2 per cent or less of hydroquinone.
Hydroxychloroquine
1-Hydroxypyrido (3,2,a)-5-phenoxazone-3-carboxylic Acid
Hydroxyurea
Hydroxyzine
Hygromycin except:
(a)when included in Schedule 6;
(b)in preparations in concentrations of 50 mg/kg or less of hygromycin.
Hyoscine Butylbromide
Hypothalmic Releasing Factors when used for diagnostic purposes.
Ibufenac
Ibuprofen
Idoxuridine except when included in Schedule 3.
Imipramine
Indapamide
Indomethacin
Inositol Nicotinate, for internal use.
Ion-exchange Resins, anionic and cationic, for internal use in humans.
Iopamidol
Ipratropium
Iproniazid
Iron compounds, injectable preparations for human therapeutic use.
Isoaminile
Isocarboxazid
Isoconazole except when included in Schedule 3.
Isoetharine
Isometheptene
Isoniazid and its derivatives.
Isoprenaline
Isopropamide except when included in Schedule 2.
Isotretinoin
Isoxuprine
Kanamycin
Ketamine
Ketoprofen
Khellin
Kitasamycin, except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic principles.
Labetalol
Latamoxef
Laudexium Methylsulphate
Lead Compounds for human therapeutic use.
Lefetamine
Leptazol
Levallorphan
Levamisole
(a)for human therapeutic use;
(b)in preparations for the prevention or treatment of heartworm in dogs.
Levodopa
Lidoflazine
Lignocaine except when included in Schedule 2.
Lincomycin
Lindane for human therapeutic use except when included in Schedule 2.
Liothyronine Sodium (Triiodothyronine)
Lithium salts for therapeutic use, except in preparations containing 0.01 per cent or less of lithium.
Loperamide
Lorazepam
Loxapine
Luteinizing Hormone (see Gonadotrophins)
Lymecycline
Mafenide
Maldison for human therapeutic use except when included in Schedule 2.
Maprotiline
Mazindol
Mebeverine
Mebhydrolin
Mecamylamine
Meclofenoxate
Meclozine
Medazepam
Mefenamic Acid except when included in Schedule 3.
Mefloquine
Mefruside
Mepacrine
Mepenzolate
Mephenesin and its derivatives except guaiphenesin where specified in Schedule 2 or 4.
Mephentermine
Mepivacaine
Meprobamate
Mepyramine except when included in Schedule 3.
Mercaptopurine and other substances structurally derived therefrom with cytotoxic properties when used for therapeutic purposes.
Mercurous Chloride for internal therapeutic use.
Mercury, organic compounds of, for therapeutic use, except when included in Schedule 2.
Metaraminol
Metformin
Methacycline
Methandienone
Methandriol
Methanthelinium
Methazolamide
Methdilazine except when included in Schedule 3.
Methenolone
Methicillin
Methimazole
Methixene
Methocarbamol
Methoin
Methotrexate
Methoxsalen
Methoxyflurane for therapeutic use.
Methsuximide
Methylandrostanolone
Methyldopa
Methylpentynol and other substituted alkynes for internal use.
Methyprylone
Metoclopramide
Metolazone
Metoprolol
Metrizamide
Metronidazole
Metyrapone
Mexiletine
Mezolcillin
Mianserin
Mibolerone
Miconazole except when included in Schedule 3.
Minocycline
Minoxidil
Mithramycin
Mitobronitol
Mitomycin
Mitozantrone
Monensin except:
(a)in animal feeds containing 33 mg/kg or less of antibiotic principles; or
(b)when included in Schedule 6.
Monoamine Oxidase Inhibitors including all substances not elsewhere specified in these Schedules for which monoamine oxidase inhibition is claimed, except triparanol.
Monobenzone for human therapeutic use except in preparations containing 2 per cent or less of monobenzone.
Moperone
Mustine and other substances structurally derived therefrom with cytotoxic properties, when used for therapeutic purposes.
Nalbuphine
Nalidixic Acid
Nalorphine
Naloxone
Nandrolone
Naproxen except when included in Schedule 3.
Narasin except:
(a)when included in Schedule 6.
(b)in animal feeds containing 100 mg/kg or less of narasin.
Natamycin
Neomycin except when included in Schedule 6.
Neostigmine
Netilmicin
Nialamide
Nicocodine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg of nicocodine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of nicocodine;
except when included in Schedule 2.
Nicodicodine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg of micodicodine per dosage unit; or
(b)in undivided preparations with a concentration of more than 2.5 per cent of nicodicodine;
except when included in Schedule 2.
Nicotine, in chewing tablets containing 4 mg or less of nicotine per tablet, for use as an aid in withdrawal from tobacco smoking.
Nicotinic Acid, where the recommended daily dose exceeds 250 mg.
Nicotinyl Alcohol for internal use.
Nicoumalone for therapeutic use.
Nifedipine
Nifenazone
Nikethamide
Niridazole
Nitrazepam
Nitrofuran and its derivatives for human therapeutic use, except when included in Schedule 3.
Nitrous Oxide for therapeutic use.
Nomifensine
Noradrenaline (excluding its derivatives)
Norcodeine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg of norcodeine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of norcodeine;
except when included in Schedule 2.
Norethandrolone
Nortriptyline
Novobiocin except when included in Schedule 6.
Nystatin
Octamylamine
Octatropine
Oleandomycin except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic principles.
Opipramol
Orciprenaline
Organophosphorus Compounds with anticholinesterase activity for human therapeutic use, not elsewhere specified in this Schedule or Schedule 2.
Ornidazole
Ornipressin
Orphenadrine
Orthocaine
Orthopterin
Oxacillin
Oxandrolone
Oxazepam
Oxolinic Acid
Oxprenolol
Oxyburprocaine
Oxymesterone
Oxymetholone
Oxyphenbutazone
Oxyphencyclimine
Oxyphenonium
Oxytetracycline except when included in Schedule 6.
Oxytocin
Pamaquine
Pancuronium
Paracetamol when combined with aspirin, caffeine or salicylamide or any derivative of these substances.
Paraldehyde
Paramethadione
Paromomycin
Pemoline
Pempidine
D-Penicillamine
Pentamethonium
Penthienate
Pentobarbitone when packed and labelled for injection.
Pentolinium
Perhexiline
Phenacemide and other substances structurally derived from acetylurea with anticonvulsant properties when used for therapeutic purposes.
Phenacetin for therapeutic use.
Phenazone except when included in Schedule 2.
Phenazopyridine
Phenelzine
Phenethicillin except when included in Schedule 6.
Phenformin
Phenglutarimide
Phenindione for therapeutic use.
Pheniprazine
Pheniramine except when included in Schedule 2 or 3.
Phenoxybenzamine
Phenoxymethylpenicillin except when included in Schedule 6.
Phensuximide and other substances not elsewhere specified in this Schedule which are structurally derived from succinamide with anticonvulsant propeties when used for therapeutic purposes.
Phentermine
Phenthimentonium
Phentolamine
Phenyapin
Phenylbutazone
Phenylpropanolamine except when included in Schedule 3.
Phenyltoloxamine except when included in Schedule 3.
Phenytoin and other substances not elsewhere specified in this Schedule which are structurally derived from hydantoin with anticonvulsant properties when used for therapeutic purposes.
Pholcodine when compounded with one or more other medicaments:
(a)in divided preparations containing not more than 100 mg or pholcodine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of pholcodine;
except when included in Schedule 2.
Physostigmine
Picrotoxin
Pilocarpine except in preparations containing 0.025 per cent or less of pilocarpine.
Pimozide
Pindolol
Pipenzolate
Piperacillin
Piperidolate
Pipobroman
Pipradrol
Piroxicam
Pituitary, its extracts and active principles or their synthetic substitutes except where separately specified in this Schedule.
Pizotifen
Podophyllum Resin (Podophyllin)
(a)for internal human use;
(b)for external human use except when included in Schedule 2 or 3.
Polymethylene Bistrimethyl Ammonium Compounds
Polymyxin
Potassium Perchlorate for therapeutic use.
Pramoxine except when included in Schedule 2.
Prazepam
Pregnenolone Acetate except in preparations for topical use.
Prenylamine
Prilocaine
Primaquine
Primidone
Probenecid
Probucol
Procainamide
Procaine
Procarbazine
Prochlorperazine
Procyclidine except when included in Schedule 2.
Proguanil
Prolintane
Promethazine except when included in Schedule 2 or 3.
Propanidid
Propantheline except when included in Schedule 2.
Propoxur for human therapeutic use except when included in Schedule 2.
Propranolol
Propylhexedrine except when included in Schedule 2.
Proquazone
Prostaglandins except where separately specified in this Schedule.
Prostianol, for treatment of animals.
Prothionamide
Protirelin (thyrotrophin releasing factor).
Protriptyline
Proxymetacaine
Pyridostigmine
Pyrimethamine
Quinethazone
Quinidine
Ranitidine
Rauwolfia Serpentina
Rifampicin
Ritodrine
Rolitetracycline
Rosoxacin
Salbutamol except when included in Schedule 3.
Salicylamide when combined with aspirin, caffeine or paracetamol or any derivatives of these substances.
Salinomycin except
(a)in animal feeds containing 60 mg/kg or less of the total antibiotic principle;
(b)when included in Schedule 6.
Selenium except—
(a)when included in Schedule 5 or 6;
(b)when included in animal feed containing 0.1 g/tonne or less of selenium in total feed;
(c)in compressed pellets for control of selenium responsive conditions in sheep;
(d)in fertilizers containing 200g/tonne or less of selenium.
Sex Hormones and all substances having sex hormonal activity not elsewhere specified in these Schedules.
Silver Sulphadiazine
Sisomycin
Sodium Cellulose Phosphate for human internal use.
Sodium Cromoglycate except when included in Schedule 3.
Sodium Fluoride, in preparations for human ingestion except when included in Schedule 2.
Sodium Nitroprusside, for human therapeutic use.
Sodium Valproate
Sontoquine
Sotalol
Sparteine
Spectinomycin
Spiramycin, except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion in pigs or poultry containing 50 mg/kg or less of antibiotic principles.
Spironolactone
Stanolone
Stanozolol
Streptomycin except when included in Schedule 6.
Strophanthus and its glycosides.
Strychnine in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.
Sulfametrole
Sulindac
Sulphanilamide, and its derivatives except:
(a)when included in Schedule 6;
(b)sulphaquinoxaline when incorporated in baits for the destruction of vermin and in animal feedstuffs containing 200 mg/kg or less of sulphaquinoxaline;
(c)oryzaline;
(d)when specifically named in this or any other Schedule.
Sulphatroxazole, for the treatment of animals.
Sulphinpryazone
Sulphomyxin
Sulphonal and alkyl sulphonals.
Sulthiame
Suxamethonium
Tacrine
Tamoxifen
Temazepam
Teniposide
Terbutaline except when included in Schedule 3.
Teropterin
Tetrabenazine
Tetracosactrin
Tetracycline except when included in Schedule 6.
Thenyldiamine except when included in Schedule 2 or 3.
Theophylline except when included in Schedule 3.
Thiacetarsamide, in preparations for the prevention or treatment of heart worm in dogs.
Thiacetazone
Thiambutosine
Thiazosulphone
Thiotepa and other substances structurally derived therefrom with cytotoxic properties when used for therapeutic purposes.
Thiothixene
Thiouracil and substances structurally derived therefrom with antithyroid properties when used for therapeutic purposes.
Thiourea for therapeutic use.
Thyroid and its extracts, and its active principles except where separately specified in this Schedule.
Thyrotrophin (T.S.H.O)
Thyroxine Sodium
Tiamulin except:
(a)when included in Schedule 6;
(b)in prepared animal feeds
Ticarcillin
Tiemonium
Tigloidine
Timolol
Tinidazole
Tipepidine
Tobramycin
Tocainide
Tolazamide
Tolazoline for internal use.
Tolbutamide
Tolpropamine
Tranexamic Acid
Tranylcypromine
Tretamine
Triamterene
Triaziquone
Triazolam
Trichloroethylene for therapeutic use.
Triclofos
Tricyclamol
Tridihexethyl
Trifluperidol
Trimeprazine except when included in Schedule 2 or 3.
Trimetaphan
Trimethoprim
Trimipramine and other compounds structurally derived therefrom by substitution in the side chain.
Trimustine
Trioxysalen
Tripelennamine
Triprolidine except when included in Schedule 2 or 3.
Troxidone and other substances not elsewhere specified in this Schedule which are structurally derived from oxazolidinone with anticonvulsant properties when used for therapeutic purposes.
Tylosin except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 50mg/kg or less of antibiotic principles; or
(c)in milk replacers for calves and starter rations for pigs containing 100 mg/kg or less of antibiotic principles.
Urethane (excluding its derivatives), for therapeutic use.
Urethanes and Ureides having or purporting to have soporific hypnotic or narcotic properties not specifically included in this or any other Schedule.
Vaccines, sera, toxoids, and antigens for human parenteral use.
Vaccines, veterinary live virus.
Valnoctamide
Vasopressin
Verapamil
Veratrum for therapeutic use.
Vercuronium
Vidarabine
Vinca Alkaloids, including semi-synthetic derivatives.
Viprynium
Virginiamycin except:
(a)when included in Schedule 6;
(b)in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic principles.
Visnadine
Vitamin A in preparations containing more than 10,000 international units per recommended daily dosage for human use.
Vitamin D in preparations containing more than 25 micrograms per recommended daily dosage for human use.
Warfarin for therapeutic use.
Xanthine Oxidase Inhibitors not elsewhere specified in this Schedule.
Xanthinol Nicotinate
Xylazine
Yohimbine
Zeranol except when included in Schedule 6.
SCHEDULE 5 Section 3
Acetic Acid (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid except:
(a)when included in Schedule 2 or 6; or
(b)for therapeutic use.
Acetic Anhydride (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic anhydride except:
(a)when included in Schedule 6; or
(b)for therapeutic use.
Acetone except:
(a)in preparations containing 25 per cent or less of designated solvents included in Schedule 5; or
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name (s) and proportion (s) of ketones included in Schedule 5.
Aklomide
Alkaline Salts, being the carbonate, orthosilicate, metasilicate or tribasic phosphate salts of sodium or potassium, and in any combination, except:
(a)in preparation containing 10 per cent or less of combined substances;
(b)in solid dose preparations whose pH in 1 per cent (w/v) aqueous solution is 11.5 or less; or
(c)in liquid preparations having a pH of 11.5 or less.
Alloxydim
Ametryn
Amines (see Epoxy Resins)
Amitrole
Ammonia and Ammonium Hydroxide (excluding their salts and derivatives) in preparations containing 5 per cent or less of free ammonia except:
(a)in preparations for human internal therapeutic use;
(b)in preparations for inhalation when absorbed in an inert solid material; or
(c)in preparations containing 0.5 per cent or less of free ammonia.
Ammonium Thiocyanate
Anhydrides (see Epoxy Resins)
Arsenic, organic compounds of, not elsewhere specified in this Schedule, in herbicides or defoliant preparations containing 3 per cent or less of arsenic.
Azamethiphos
Barium Silicofluoride when coated on paper in an amount not exceeding 8 mg per sq. cm.
Bendiocarb in preparations containing 2 per cent or less of bendiocarb.
Bentazone
Benzoyl Peroxide except:
(a)when included in Schedule 2, 3 or 4; or
(b)in preparations containing 2 per cent or less of benzoyl peroxide.
S-Benzyl N, N-di- (sec-butyl)-thiolocarbamate.
BHC (excluding the gamma-isomer) in preparations containing 10 per cent or less of BHC.
Bioallethrin including sinbioallethrin except in preparations containing 10 per cent or less of bioallethrin.
Bioresmethrin, except in preparations containing 10 per cent or less of bioresmethrin.
Boric Acid (excluding its salts) and Borax except:
(a)when included in Schedule 4; or
(b)in preparations, other than insect baits, containing 1 per cent or less of boron; or
(c)in hand cleaning preparations.
Buthidazole
Butoxycarboxim in solid preparations containing 10 per cent or less of butoxycarboxim.
Cadmium Sulphide in preparations containing 2.5 per cent or less of cadmium sulphide for human therapeutic use.
Calcium Hypochlorite and preparations containing more than 4 per cent of available chlorine.
Camphor except:
(a)in preparations containing 10 per cent or less of camphor; or
(b)when included in Schedule 4.
Carbaryl
(a)in preparations containing 10 per cent or less of carbaryl except when included in Schedule 2 or 4;
(b)when impregnated into plastic resin material containing 20 per cent or less of carbaryl.
Chlordecone in preparations containing 5 per cent or less of chlordecone.
Chlorfenac
Chlorfenson
Chlorinating Compounds and Bleaches containing more than 4 per cent of available chlorine, not elsewhere specified in these Schedules.
Chlornidine
Chlorocresol, except in preparations containing 3 per cent or less of chlorocresol.
1-(4-Chlorophenoxy)-1-imidazol-1-yl-3,3-dimethyl-2-butanone in concentrations of more than 2 per cent except when included in Schedule 4 or 6.
Chloropropylate
Chlorothalonil
Chlorsulfuron
Clanobutin, for the treatment of animals except when included in Schedule 4.
Clofentezine
Clopyralid
Copper Sulphate except for internal human therapeutic use.
4-CPA
Cuprimyxin for the treatment of animals.
Curing Agents (see Epoxy Resins)
Cyanatryn
Cyanoacrylic Acid Esters
(alpha-Cyano-4-fluoro-3-phenoxy) benzyl 3-[2-(4-chlorophenyl)-2-chlorovinyl]-2,2-dimethyl cyclopropane-carboxylate (Flumethrin), in oil based preparations containing 1 per cent or less of flumethrin.
Cyanuric Acid (excluding its salts and derivatives)
Cyclohexanone Peroxide
Cyfluthrin
(a)in wettable powders containing 10 per cent or less of cyfluthrin; or
(b)in emulsifiable concentrates containing 2 per cent or less of cyfluthrin.
Cypermethrin in preparations containing 10 per cent or less of cypermethrin.
2,4-D
2,4-DB
Dicophane (DDT) in preparations containing 10 per cent or less or dicophane except when included in Schedule 2.
2,4-DES
N,N-Diallyldichloroacetamide except in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide
Dicamba
Dichlone
Dichloroisocyanurates and their preparations containing more than 4 per cent available chlorine.
1-[2(2,4-Dichlorophenyl)-2-(2-propenyloxy)ethyl]-1H-imidazole.
Dichlorvos
(a)when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;
(b)in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals;
(c)in pressurized spray packs containing 10 grams or less of dichlorvos.
Diclobutrazol
Dicloran
Dicofol
Dimethirimol
Dimethylformamide in preparations containing 10 per cent or less of dimethylformamide.
Dinitramine
Diphenamid
Dodine
DSMA in herbicides or defoliant preparations containing 3 per cent or less of arsenic.
Epoxy Resins Liquid and all amines and organic anhydrides used as curing agents for epoxy resins.
EPTC
Ethephon (excluding its salts and derivatives).
Ether in preparations containing more than 10% of ether for use in internal combustion engines.
Ethofumesate
Ethoxyquin except in preparations containing 10 per cent or less of ethoxyquin.
Ethylene Glycol when packed and labelled as a boiling point and/or freezing point modifier and containing 10 mg/kg of denatonium benzoate as a bittering agent.
Fenarimol
Fenbutatin-oxide
Fenoprop
Fenson
Fenthion in preparations containing 20 per cent or less of fenthion when packed in single-use containers having a capacity of 1.0 ml or less.
Flamprop-methyl
Fluchloralin
Formic Acid (excluding its salts and derivatives).
Fospirate when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.
Furalaxyl
Glutaraldehyde, in preparations containing 5 per cent or less of glutaraldehyde, except when included in Schedule 2.
Glyphosate
Hexazinone
Hydrocarbons, Liquid, including kerosene, mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives) distilling under 300oC, except:
(a)toluene and xylene when included in Schedule 6;
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name (s) and proportion (s) of hydrocarbons;
(c)in solid or semi-solid cleaning and polishing preparations;
(d)in preparations containing 25 per cent or less of designated solvents included in Schedule 5;
(e)in preparations packed in pressurized aerosol containers;
(f)in adhesives packed in containers each containing 50 grams or less of adhesive.
Hydrochloric Acid (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HC1) except:
(a)in preparations containing 0.5 per cent or less of hydrochloric acid (HC1); or
(b)for therapeutic use.
Hydrofluoric Acid and Hydrosilicofluoric Acid in preparations containing 0.5 per cent or less of hydrofluoric acid or hydrosilicofluoric acid except in substances containing 15 mg/kg or less of fluoride ion.
Hydrogen Peroxide (exlcuding its salts and derivatives) except in preparations containing 6 per cent (20 vol) or less of hydrogen peroxide.
Iodofenphos
Kerosene, see Hydrocarbons Liquid.
Lead Compounds, in preparations for use as hair cosmetics.
Levamisole in preparations containing 15 per cent or less of levamisole for the treatment of animals, except when included in Schedule 4.
Lindane in preparations containing 10 per cent or less of lindane except when included in Schedule 2.
Maldison in preparations containing 10 per cent or less of maldison except:
(a)when included in Schedule 2; or
(b)in dust preparations containing 2 per cent or less of maldison.
Mancozeb
Maneb
MCPA
MCPB
Mecoprop
Mepiquat
Metalaxyl
Metaldehyde in preparations containing 2 per cent or less of metaldehyde.
Methabenzthiazuron
Methanol (excluding its derivatives) in preparations containing 10 per cent or less of methanol except in preparations containing 2 per cent or less of methanol.
Methazole
Methiocarb in pelleted preparations containing 2 per cent or less of methiocarb.
Methoxychlor
Methylated Spirits: Methylated spirt, industrial, as defined by the Spirits Act 1906, (excluding its preparations and admixtures) except in containers having a capacity of more than 5 litres.
Methylene Chloride except when used in aerosols.
Methylene Dianiline (see Epoxy Resins)
Methyl Ethyl Ketone except:
(a)in preparations containing 25 per cent or less of designated solvents included in Schedule 5; or
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name(s) and proportion(s) of ketones included in Schedule 5.
Methyl Ethyl Ketone Peroxide
Methyl Iso-amyl Ketone except:
(a)in preparations containing 25 per cent or less of designated solvents included in Schedule 5; or
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name(s) and proportion(s) of ketones included in Schedule 5.
Methyl Iso-butyl Ketone except:
(a)in preparations containing 25 per cent or less of designated solvents included in Schedule 5; or
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name(s) and proportion(s) of ketones included in Schedule 5.
Methyl Salicylate in liquid preparations containing 25 per cent or more of methyl salicylate except when included in Schedule 6.
N-(3-Methyl-4-thiazolin-2-ylidene)-2,4-xylinden (Cymiazole)
Metiram
Metolachlor
Metribuzin
Mezineb
Mineral Turpentine, see Hydrocarbons Liquid.
MSMA in herbicides or defoliant preparations containing 3 per cent or less of arsenic.
NAA—see Naphthalen Acetic Acid
Naled when impregnated in plastic resin strip material containing 20 per cent or less of naled.
Naphthalene as such.
Naphthalene Acetic Acid, except in preparations containing 25 per cent or less of naphthalene acetic acid.
Naptalam
Nitric Acid (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid as such, except preparations containing 0.5 per cent or less of nitric acid.
Norbormide
Ofurace
Organo-tin Compounds—see Tin Organic Compounds
Oxadixyl
Oxycarboxin
Oxythioquinox
Paradichlorobenzene
Pebulate
Penconazole
Pendimethalin
Peracetic Acid in concentrations of 10 per cent or less.
Petrol when packed in containers of 20 litres or less except preparations containing 25 per cent or less of petrol.
Phenisopham
ortho-Phenylphenol except in preparations containing 3 per cent or less of ortho-phenylphenol.
Phosphonic Acid, except in preparations containing 10 per cent or less of phosphonic acid.
Phosphoric Acid, excluding its salts and derivatives, except:
(a)when packed in containers with a capacity of not less than 10 litres and labelled with the word “CORROSIVE”, in bold face sanserif capital letters of a height of not less than 1 cm;
(b)in preparations containing 350 g/litre or less of phosphoric acid;
(c)in solid and semi-solid preparations; or
(d)in professional dental kits.
Pirimicarb in preparations containing 0.5 per cent or less of pirimicarb.
Poly (Hexamethylene Biguanide), except in preparations containing 5 per cent or less of poly (hexamethylene biguanide).
Potassium Chlorate except:
(a)when included in Schedule 2; or
(b)in preparations containing 10 per cent or less of potassium chlorate.
Potassium Hydroxide (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide, except in preparations containing 0.5 per cent or less of potassium hydroxide.
Potassium Sulphide in preparations for metal treatment in containers each containing 50 g or less of potassium sulphide.
Prometryn
Propanil
Propiconazole in concentrations of 20 per cent or less.
Propionic Acid (excluding its salts and derivatives) in preparations containing more than 30 per cent of propionic acid, except:
(a)when included in Schedule 6; or
(b)for therapeutic use.
Propoxur
(a)in dust preparations containing 3 per cent or less of propoxur;
(b)in granular sugar-based fly baits containing 1 per cent or less of propoxur providing that the preparation also contains a dark colouring agent and separate bittering agent;
(c)in aerosol packs containing 10 g or less of propoxur;
(d)in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.
Prynachlor
Pyrethrins, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except in preparations containing 10 per cent or less of such substances.
Pyrinuron in preparations containing 10 per cent or less of pyrinuron.
Quaternary Ammonium Compounds in preparations containing more than 10 per cent of quaternary ammonium compounds except when included in any other Schedule.
Quintozene
Salicylanilide
Secbumeton
Selenium Sulphide in preparations containing 2.5 per cent or less of selenium sulphide for topical therapeutic use.
Sethoxydim
Sodium Chlorate
Sodium Hydrogen Sulphate
Sodium Hydroxide (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide except in preparations containing 0.5 per cent or less of sodium hydroxide.
Sodium Hypochlorite and preparations containing more than 4 per cent of available chlorine.
Sodium Nitrite except:
(a)in preparations containing 1 per cent or less of sodium nitrite; or
(b)when included in Schedule 2.
Sodium Sulphide in preparations for metal treatment in containers each containing 50 g or less of sodium sulphide.
Styrene (excluding its derivatives) except in containers having a capacity of more than 20 litres provided the containers are marked with the name and proportion of styrene.
Sulphamic Acid, except in preparations containing 10 per cent or less of sulphamic acid.
2,3,6-TBA
TCA—see Trichloroacetic Acid.
TDE in preparations containing 10 per cent or less of TDE.
Terbumeton
Terbutryn
Tetrachloroethylene in preparations containing 5 per cent or less of tetrachloroethylene except:
(a)when prepared for use for the treatment of humans and for the treatment of animals; or
(b)when absorbed into an inert solid.
Tetrachlorvinphos, except in animal feedstuffs containing 0.2 per cent or less of tetrachlorvinphos.
Tetramethrin except in aerosol packs.
Thiobencarb
Tin Organic Compounds not elsewhere included in this Schedule in preparations containing 1 per cent or less of such compounds.
Triadimefon, in wettable powders containing 25 per cent or less of triadimefon.
Triadimenol
Tri-allate
Trichloroacetic Acid, alkali salts of.
1,1,1-Trichloroethane except:
(a)in preparations containing 25 per cent or less of designated solvents included in Schedule 5;
(b)when used in aerosols other than for therapeutic use; or
(c)in containers having a capacity of more than 20 litres provided the containers are marked with the name and proportion of 1,1,1-trichloroethane.
Trichloroisocyanuric Acid in compressed block form for use in swimming pools or toilet cisterns.
Trietazine
Turpentine Oil when packed in containers of 20 litres or less except in preparations containing 25 per cent or less of turpentine oil.
Vernolate
Warfarin, in rodent baits containing 0.1 per cent or less of warfarin.
Zineb
Ziram
SCHEDULE 6 Section 3
Acephate
Acetic Acid (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid, except when included in Schedule 2.
Acetic Anhydride (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic anhydride, except for therapeutic use.
Acifluorfen
Aldrin
Allidochlor
Alpha-chlorohydrin
Amidothion
2-Amino-butane
Aminocarb in preparations containing 25 per cent or less of aminocarb.
Amitraz
Ammonia and Ammonium Hydroxide (excluding their salts and derivatives) except:
(a)when included in Schedule 5;
(b)in preparations for human internal therapeutic use;
(c)in preparations for inhalation when absorbed in an inert solid material; or
(d)in preparations containing 0.5 per cent or less of free ammonia.
Aniline (excluding its salts and derivatives) except in preparations containing 1 per cent or less of aniline.
Arecoline
Arsenic, except where separately specified in this Schedule:
(a)in ant poisons containing 0.4 per cent or less of arsenic;
(b)organic compounds of arsenic in herbicides or defoliant preparations except when included in Schedule 5;
(c)in animal feed premixes containing 4 per cent or less of arsenic;
(d)in preparations for the treatment of animals except thiacetarsamide when included in Schedule 4;
(e)in paints containing more than 0.1 per cent of arsenic when calculated on the basis of the non-volatile content of the paint.
Avermectin B1, in preparations containing 10 mg/ml or less of avermectin B1, for the treatment of animals, when supplied in sealed containers for use in automatic injection equipment.
Azobenzene
Azocyclotin
Bacitracin in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Barban
Barium, salts of (except barium sulphate) except:
(a)paint containing barium metaborate; or
(b)when included in Schedule 5.
Bendiocarb
(a)in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;
(b)in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when pakced in containers or primary packs containing not less than 48g of bendiocarb and labelled for use as a fly control preparation; or
(c)in insoluble granular preparations containing 5 per cent or less of bendiocarb,
except when included in Schedule 5.
Benomyl
Benquinox
Bensulide
5-Benzylfur-3-ylmethyl (1’R,3’S.E)-2’,2’-dimethyl-3’-(2-oxo-2,3,4,5-tetrahydro-3-thienylidenemethyl)-cyclopropane Carboxylate
Benzylpenicillin including procaine penicillin in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of benzylpenicillin or procaine penicillin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Beryllium
BHC (excluding the gamma-isomer) except when included in Schedule 5.
Binapacryl
Bithionol for treatment of animals.
Brodifacoum in preparations containing 0.25 per cent or less of brodifacoum.
Bromadiolone in preparations containing 0.25 per cent or less of bromadiolone.
Bromoform except for therapeutic use.
Bromophos
Bromophos-ethyl
Bromoxynil
Brotianide
Bunamidine
Butacarb
Butoxycarboxim except when included in Schedule 5.
2-Butoxy-2’-thiocyano-diethyl Ether
Butynorate
Cacodylic Acid in animal feed premixes containing 4 per cent or less of arsenic.
Cadmium, compounds of, except when included in Schedule 5.
Calciferol in rodent baits.
Cambendazole
Carbaryl except when included in Schedule 2, 4 or 5.
Carbendazim
Carbon Disulphide
alpha-Chloralose, when prepared for use as a pesticide.
Chlordane
Chlordecone except when included in Schedule 5.
Chlorfenethol
Chlormequat
N-[5-Chloro-4-[(4-chlorophenyl)-cyanomethyl]-2-methylphenyl]-2-hydroxy-3,5-diiodobenzamide
Chloroform (excluding its derivatives) except:
(a)when in Schedule 2 or 4; or
(b)in preparations containing 10 per cent or less of chloroform where the chloroform content is declared on the label.
Chloromethiuron
Chlorophacinone
1-(4-Chlorophenoxy)-1-imidazol-1-y1-3,3-dimethyl-2-butanone in concentrations of more than 40 per cent except when included in Schedule 4.
Chloropicrin in preparations containing 5 per cent or less of chloropicrin.
Chlorpyrifos
Chlorpyrifos-methyl
Chlortetracycline in preparations:
(a)for topical application to animals for ocular use only;
(b)in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of chlortetracycline when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Chlorthiamid
Chromates and Dichromates
Chromium Trioxide (excluding its salts and derivatives).
Coumaphos in preparations containing 5 per cent or less of coumaphos.
Coumarin and phenylindanedione derivatives except:
(a)when included in Schedule 4; or
(b)where separately specified in this Schedule.
Coumatetralyl
Creosote, except:
(a)when included in Schedule 2; or
(b)in preparations containing 3 per cent or less of phenols.
Crotoxyphos
Crufomate
Cyanazine
(alpha-Cyano-4-fluoro-3-phenoxy) benzyl 3-[2-(4-chlorophenyl)-2-chlorovinyl]-2,2-dimethyl cyclopropane-carboxylate (Flumethrin), except when included in Schedule 5.
Cyfluthrin except:
(a)when included in Schedule 5; or
(b)in pressurized spray packs containing 1 per cent or less of cyfluthrin.
Cyhexatin
Cyometrinil
Cypermethrin except when included in Schedule 5.
Cythioate
Dazomet
Dicophane (DDT) and its preparations containing more than 10 per cent of dicophane, except when included in Schedule 2.
Deltamethrin in aqueous formulation containing 1 per cent or less of deltamethrin, when no other organic solvent, other than a glycol, is present.
Demeton-O-methyl and Demeton-S-methyl in preparations containing 50 per cent or less of one or both demeton-0-methyl and demeton-S-methyl.
Di-allate
Diazinon
Dichlofenthion
Dichloroethyl Ether
N-(3,4-Dichlorophenyl)-N’-[2-(2“sulfoxy-4’-chlorphenoxy)-5 chlorphenyl] urea (sodium salt)
1,2-Dichloropropane
1,3-Dichloropropene
Dichlorvos in preparations containing 50 per cent or less of dichlorvos except when included in Schedule 5.
Diclofop-methyl
Dieldrin
Diethylene Dioxide
Difenacoum in preparations containing 0.25 per cent or less of difenacoum.
Difenzoquat
Dihydrostreptomycin in preparations for intramammary infusion in animals containing not more than 100 000 international units per dose of dihydrostreptomycin when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Dimethanonaphthalene and all substitution and/or addition products of, not elsewhere specified in these Schedules.
Dimethipin
Dimethoate
1,3-Di (methoxycarbonyl)-1-propen-2-yl-dimethyl Phosphate in preparations containing 25 per cent or less of 1,3-di (methoxycarbonyl)-1-propen-2-yl-dimethyl phosphate.
Dimethyl Formamide except when included in Schedule 5.
Dimethyl Sulphoxide
(a)when not for therapeutic use; or
(b)for the treatment of animals:
(i)when combined with no other therapeutic substance; or
(ii)in preparations containing copper salicylate as the only other therapeutic substance.
Dimetilan in preparations containing 25 per cent or less of dimetilan.
Dimetridazole
Dinitrocresols and their homologues, not elsewhere specified in this Schedule, in preparations containing 5 per cent or less of such compounds except when included in Schedule 4.
Dinitrophenols and their homologues, not elsewhere specified in this Schedule, in preparations containing 5 per cent or less of such compounds except when included in Schedule 4.
Dinocap
Dinoseb in preparations containing 5 per cent or less of dinoseb.
Dioxacarb
Diphacinone
Diquat
Disulfiram except when included in Schedule 4.
Disulfoton in granular preparations containing 5 per cent or less of disulfoton.
Dithianon
Dithiazanine in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.
Dithiocarbamates when prepared for agricultural or horticultural purposes, except when specified in Schedule 5.
3,3’-Di-(trifluoromethyl)-4,4’-dichloro-N,N’-diphenylurea
Diuredosan
DSMA in herbicides or defoliant preparations except when included in Schedule 5.
Econazole for external treatment of animals.
Endosulfan
Endothal
Epichlorohydrin except in preparations containing 2 per cent or less of epichlorohydrin.
Erythromcyin:
(a)in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of erythromycin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose;
(b)in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Etaconazole
Ether, except:
(a)when included in Schedule 2, 4 or 5; or
(b)in preparations containing, 10% or less of ether.
Ethiofencarb
Ethoate-methyl
Ethoprophos in granular formulations containing 10 per cent or less of ethoprophos.
Ethyl Bromide
Ethylene Chlorohydrin
Ethylene Dichloride
Ethylene Glycol, when packed and labeled as an anti-freeze, except when included in Schedule 5.
Ethylene Glycol Monoalkyl Ethers and their Acetates except:
(a)in preparations containing 10 per cent or less of such substances; or
(b)in containers of a capacity of 20 litres or more provided the container is labelled with the warning “POISON”, the name and quantity of the ether, the name of the manufacturer or the trade mark and the warning statement ‘Avoid contact with skin and eyes and avoid breathing the vapour’.
Ethylene Oxide
Etridiazole
Etrimfos
Eucalyptus Oil except in preparations containing 25 per cent or less of eucalyptus oil.
Famphur in preparations containing 20 per cent or less of famphur.
Fenaminosulf in preparations containing 10 per cent or less of fenaminosulf when labeled and packed as dry seed dressings.
Fenamiphos in granular preparations containing 5 per cent or less of fenamiphos.
Fenazaflor
Fenchlorphos
Fenitrothion
Fenthion except when included in Schedule 5.
Fenvalerate
Ferbam
Flavophospholipol in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Fluazifop-butyl
Formaldehyde (excluding its derivatives) except in preparations containing 5 per cent or less of formaldehyde.
Formothion
Fospirate except when included in Schedule 5.
Fumagillin
Glutaraldehyde, except when included in Schedule 2 or 5.
Guazatine
Haloxon
HCB
Heptachlor
Hexachlorophane in preparations for the treatment of animals.
Hydrazine
Hydrochloric Acid (excluding its salts and derivatives) except in preparations containing 10 per cent or less of hydrochloric acid (HCI).
Hydrofluoric Acid and Hydrosilicofluoric Acid and other fluorine compounds except:
(a)when used for human therapeutic purposes;
(b)in dentifrices containing 0.1 per cent or less of fluoride ion;
(c)in preparations containing 3 per cent or less of sodium fluoride or sodium silicofluoride when used as preservatives;
(d)when included in Schedule 7, 5, 4 or 2;
(e)in substances containing 15 mg/kg or less of fluoride ion; or
(f)ammonium fluosilicate in preparations containing 3.2 per cent or less of ammonium fluosilicate for pesticide purposes.
Hydroquinone except:
(a)when included in Schedule 4; or
(b)in preparations containing 10 per cent or less of hydroquinone.
Hygromycin in animal feed premixes for use as an anthelmintic containing 2 per cent or less of antibiotic principles.
Imidocarb
Iodine (excluding its salts, derivatives and iodophors) except:
(a)when included in Schedule 2; or
(b)in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.
Iodophors except in preparations containing 1.5 per cent or less of available iodine.
Ioxynil
Iron Compounds, for the treatment of animals, except:
(a)in liquid preparations containing 0.1 per cent or less of iron; or
(b)in animal feeds and feed premixes.
Isocyanates, free organic, except in paints containing 0.1 per cent or less of free organic isocyanates.
Kitasamycin in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Lasalocid except in animal feeds containing 100 mg/kg or less of antibiotic principles.
Laurylisoquinolinium Bromide
Lead Compounds except:
(a)when included in Schedule 4 or 5;
(b)in preparations for cosmetic use containing 250 mg/kg or less of lead; or
(c)in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead.
Levamisole for the treatment of animals except when included in Schedule 4 or 5.
Lindane except when included in Schedule 2 or 5.
Maldison except:
(a)when included in Schedule 2 or 5; or
(b)in dust preparations containing 2 per cent or less of maldison.
Mebendazole for the treatment of animals.
Meclofenamic Acid for the treatment of animals.
Menazon
Mercuric Iodide when prepared for agricultural, horticultural, pastoral or industrial use.
Mercuric Thiocyanate when prepared for use for photographic purposes.
Mercurous Chloride except when included in Schedule 4.
Mercury, organic compounds of, in preparations for agricultural, pastoral or horticultural use except ethoxyethyl mercury chloride and ethyl mercury chloride in Schedule 7.
Metacresolsulphonic Acid and Formaldehyde Condensation Product for the treatment of animals.
Metaldehyde except when included in Schedule 5.
Methacrifos
Metham
Methanol (excluding its derivatives) except:
(a)when included in Schedule 5; or
(b)in preparations containing 2 per cent or less of methanol.
Methiocarb except when included in Schedule 5.
Methomyl in fly-baits containing 1 per cent or less or methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.
Methyl Chloride
Methylenebisthiocyanate except in preparations containing 1 per cent or less of methylenebisthiocyanate.
Methyl Isothiocyanate
Methyl Salicylate excluding admixtures (see also Schedule 5).
1-(B Methyl sulphonamide ethyl)-2-amino-3-N,N-diethylamino benzene
Miconazole for the external treatment of animals.
Molinate
Monensin in animal feed premixes containing 12.5 per cent or less of antibiotic principles.
MSMA in herbicides or defoliant preparations except when included in Schedule 5.
Nabam—see Dithiocarbamates.
Naled except when included in Schedule 5.
Naphthalophos when specifically prepared and packed for use as a sheep drench.
Narasin in animal feed premixes containing 120 g/kg or less of narasin.
Neomycin in preparations for topical application to animals for ocular use only.
Nicotine in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.
Nimidane in preparations containing 25 per cent or less of nimidane.
Nithiamide, except in preparations containing 20 per cent or less of nithiamide.
Nitric Acid (excluding its salts and derivatives) except in preparations containing 10 per cent or less of nitric acid as such.
Nitrobenzene except:
(a)in solid or semi-solid polishes;
(b)in soaps containing 1 per cent or less of nitrobenzene; or
(c)in preparations containing 0.1 per cent or less of nitrobenzene.
Nitrophenols, ortho, meta and para.
Nitroscanate
Nitroxynil
Novobiocin in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of novobiocin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Octhilinone
Oestradiol-17-beta
(a)in ear implants for growth promotion in bovine cattle;
(b)in combination with progesterone, testosterone or trenbolone in ear implants for growth promotion in bovine cattle.
Olaquindox in animal feed premixes for growth promotion.
Oleandomycin in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Omethoate in preparations containing 50 per cent or less of omethoate.
Organo-tin Compounds—see Tin Organic Compounds
Orthodichlorobenzene
Oxadiazon
Oxalic Acid (excluding its salts and derivatives) and soluble oxalates.
Oxantel Embonate for the treatment of animals.
Oxfendazole
Oxyclozanide
Oxytetracycline in preparations:
(a)for topical application to animals for ocular use only;
(b)for intramammary infusion in animals, containing not more than 100 000 international units per dose of oxytetracycline, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Paraquat in granular preparations containing 3 per cent or less of paraquat.
Parbendazole
Pentachlorophenol except in preparations containing 0.5 per cent or less of pentachlorophenol.
Peracetic Acid except when included in Schedule 5.
Perfluidone
Permanganates.
Phenethicillin in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of phenethicillin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Phenkapton in preparations containing 50 per cent or less of phenkapton.
Phenol and any homologue of phenol boiling below 220oC, except:
(a)when included in Schedule 2; or
(b)in preparations containing 3 per cent or less by weight of such substances.
Phenoxymethylpenicillin in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of phenoxymethylpenicillin, when suitably coloured with Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Phenylenediamines and alkylated phenylenediamines, not elsewhere specified in this Schedule:
(a)when used in hair dyes:
(b)in preparations packed and labelled for photographic purposes;
(c)in preparations packed and labelled for testing water except diethyl- or dimethyl-para-phenylene diamine in tablets containing 10 mg or less in opaque strip packaging labelled for water testing.
Phosalone
Phosmet
Phosphides, Metallic
Phosphorus Yellow (excluding its salts and derivatives) in preparations containing 0.5 per cent or less of free phosphorus.
Phoxim
Picric Acid (excluding its derivatives) except in preparations containing 5 per cent or less of picric acid.
Pindone
Piperophos
Pirimicarb except when included in Schedule 5.
Pirimiphos-ethyl
Pirimiphos-methyl
Potassium Bromate except in preparations containing 0.5 per cent or less of potassium bromate.
Potassium Cyanate
Potassium Hydroxide except in preparations containing 5 per cent or less of potassium hydroxide.
Prochloraz
Profenofos
Progesterone
(a)in a silicone rubber elastomer when used as a controlled-release implant for synchronization of oestrus in cattle;
(b)in combination with oestradiol-17-beta or trenbolone in ear implants for growth promotion in bovine cattle.
Promacyl
Promecarb in preparations containing 50 per cent or less of promecarb.
Propachlor
Propargite
Propetamphos
Propiconazole except when included in Schedule 5.
Propionic Acid (excluding its salts and derivatives):
(a)in preparations containing more than 80 per cent or propionic acid;
(b)except for therapeutic use.
Propoxur except when included in Schedule 2, 4 or 5.
Prothiofos
Pyrazophos
Pyrinuron except when included in Schedule 5.
Rafoxanide
Salinomycin in animal feed premixes containing 6 per cent or less of antibiotic principles.
Selenium, Compounds of,
(a)in preparations containing 2.5 per cent or less of selenium:
(i)when packed and labelled for the blueing of gun barrels;
(ii)when packed and labelled for photographic purposes;
(b)in preparations containing 0.1 per cent or less of selenium when packed and labelled as vaccines, drenches or pastes for treatment of animals;
(c)in preparations containing 0.5 per cent or less of selenium when packed and labelled as other injections for treatment of animals;
(d)in premixes containing 2 per cent or less of selenium when packed and labelled for incorporation into animal feeds to provide 0.1 g/tonne or less of selenium.
Sodium Bromate except in preparations containing 0.5 per cent or less of sodium bromate.
Sodium Hydroxide (excluding its salts and derivatives) except:
(a)in preparations containing 0.5 per cent or less of sodium hydroxide; or
(b)when included in Schedule 5.
Spiramycin in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Streptomycin in preparations for intramammary infusion in animals, containing not more than 100 000 international units per dose of streptomycin, when suitably coloured with a Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose.
Strychnine in grain baits containing 0.5 per cent or less of strychnine.
Sulphanilamide and its derivatives unless elsewhere specified in this Schedule when packed and labelled for treatment of ornamental caged birds or ornamental fish only.
Sulphaquinoxaline when packed and labelled for use as a coccidiostat in poultry except preparations containing 200 mg/kg or less of sulphaquinoxaline.
Sulphuric Acid (excluding its salts and derivatives) except:
(a)in fire extinguishers; or
(b)in preparations containing 0.5 per cent or less of sulphuric acid (H2SO4).
Sulprophos
2,4,5-T
TCA—see Trichloroacetic Acid.
TCMTB (2-[thiocyanomethylthio]benzothiazole).
TDE except when included in Schedule 5.
Temephos
Terbuthylazine
Terpenes, Chlorinated
Testosterone—
(a)testosterone cypionate, dipropionate, enanthate and propionate in preparations labelled for treatment and prevention of pizzle (sheath) rot in wethers;
(b)in preparations labelled for masculinisation of wethers for use as ‘teaser rams’ to stimulate and detect reproductive activity in ewes;
(c)in combination with oestradiol-17-beta or trenbolone in ear implants for growth promotion in bovine cattle; and
(d)in oil preparations for growth promotion purposes labelled for injection at the base of the ear in sheep.
Tetrachloroethylene except:
(a)when prepared for use for the treatment of humans and for the treatment of animals;
(b)in preparations containing 6 per cent or less when absorbed into an inert solid; or
(c)when included in Schedule 5.
Tetracycline in preparations:
(a)for topical application to animals for ocular use only;
(b)for intramammary infusion in animals, containing not more than 100 000 international units per dose of tetracycline, when suitably coloured with a Brilliant Blue FCF or other approved colour as a marker and when packed in applicator devices specially designed for the purpose;
(c)when packed and labelled for treatment of ornamental caged birds or ornamental fish only.
Tetradifon
Tetramisole in preparations for the treatment of animals.
Thiazafluron
Thiodicarb
Thiometon
Thiourea except for therapeutic use.
Thiram
Tiamulin for the treatment of animals:
(a)in feed premixes containing 25 per cent or less of tiamulin;
(b)in soluble concentrates containing 45 per cent or less of tiamulin.
Tin Organic Compounds, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl, not elsewhere included in these Schedules except:
(a)in plastics;
(b)in paints containing 3 per cent or less of such compounds calculated as tin as a proportion of the non-volatile content of the paint; or
(c)in other preparations containing 1 per cent or less of such compounds.
ortho-Tolidine when packed and labelled in concentrations of 0.1 per cent or less of ortho-tolidine for the testing of water.
Toluene (excluding its derivatives), except:
(a)in preparations containing 50 per cent or less of toluene or toluene and xylene; or
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name and proportion of toluene or toluene and xylene.
Trenbolone
(a)in ear implants for growth promotion in bovine cattle;
(b)in combination with oestradiol-17-beta, progesterone or testosterone in ear implants for growth promotion in bovine cattle.
Triadimefon, except when included in Schedule 5.
S,S,S-Tributylphosphorothioate
Trichlorfon
Trichloroacetic Acid except when included in Schedule 5.
Trichloroethylene except:
(a)when included in Schedule 4; or
(b)for other human therapeutic use.
Trichlorophenol
Triclopyr
Tridemorph
Triethyl Phosphate
Trifluoromethane Sulphonic Acid
Tylosin in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Vamidothion
Virginiamycin in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic principles.
Warfarin, except when included in Schedule 4 or 5.
Xylene (excluding its derivatives), when packed in containers of 20 litres or less except:
(a)in preparations containing 50 per cent or less of xylene or xylene and toluene; or
(b)in containers having a capacity of more than 20 litres provided the containers are marked with the name and proportion of xylene or xylene and toluene.
Zeranol, in ear implants for use as a growth promotant in steer cattle.
Zinc Chloride except in preparations containing 5 per cent or less of zinc chloride.
Zinc p-Phenolsulphonate except in preparations containing 5 per cent or less of zinc p-phenolsulphonate.
Zinc Sulphate except for human therapeutic use and in preparations containing 5 per cent or less of zinc sulphate.
SCHEDULE 7 Section 3
Acrolein
Acrylonitrile
Alachlor
Aldicarb
Allyl Alcohol
Aminocarb except when included in Schedule 6.
4-Aminopyridine
Amiton
ANTU
Arprinocid
Arsenic, except:
(a)thiacetarsamide when included in Schedule 4;
(b)when included in Schedule 5 or 6; or
(c)in animal feed containing 75g/tonne or less of arsenic.
Avermectin B1, except when included in Schedule 6.
Azinphos-ethyl
Azinphos-methyl
Bendiocarb except when included in Schedule 5 or 6.
Benzene (excluding its derivatives) except:
(a)preparations containing 1.5 per cent v/v or less of benzene; or
(b)petrol containing 5 per cent v/v or less of benzene.
Betahydroxyethylhydrazine
Brodifacoum except when included in Schedule 6.
Bromadiolone except when included in Schedule 6.
Camphechlor
Captafol
Captan
Carbadox
Carbofuran
Carbon Tetrachloride
Carbophenothion
Chlordimeform
Chlorfenvinphos
Chlorine (excluding its salts and derivatives).
5-Chloro-3-methyl-4-nitropyrazole
Chloropicrin except when included in Schedule 6.
Chlorthiophos
Coumaphos except when included in Schedule 6.
Cyanides—see hydrocyanic acid.
Cyhalothrin
Deltamethrin except when included in Schedule 6.
Demeton
Demeton-O-methyl and Demeton-S-methyl except when included in Schedule 6.
Dialifos
1,2,-Dibromo-3-chloropropane
Dichlorvos except when included in Schedule 5 or 6.
Dicrotophos
Dienochlor
Difenacoum except when included in Schedule 6.
Dimefox
1,3-Di(methoxycarbonyl)-1-propen-2-yl-dimethyl Phosphate except when included in Schedule 6.
Dimetilan except when included in Schedule 6.
Dinitrophenols and their homologues, not elsewhere specified in this Schedule, except when included in Schedule 4 or 6.
Dinitrocresols and their homologues, not elsewhere specified in this Schedule, except when included in Schedule 4 or 6.
Dinoseb except when included in Schedule 6.
Dioxathion
Disulfoton except when included in Schedule 6.
Endrin
Ethion
Ethoprophos except when included in Schedule 6.
Ethoxyethyl Mercury Chloride
Ethylene Dibromide
Ethyl Mercury Chloride
Famphur except when included in Schedule 6.
Fenaminosulf except when included in Schedule 6.
Fenamiphos except when included in Schedule 6.
Fensulfothion
Fenthionethyl
Flucythrinate
Flunixin Meglumine, except when included in Schedule 4.
Fluoroacetamide
Fluoroacetic Acid
Folpet
Formetanate
Halofuginone except in prepared stockfeeds containing 3 g/tonne or less of halofuginone.
Hydrocyanic Acid and Cyanides except when included in Schedule 1 or 2.
Isocarbophos
Isofenphos
Ivermectin
Leptophos
Mazidox
Mecarbam
Mercuric Chloride when prepared for use for agricultural, industrial, pastoral or horticultural purposes.
Methamidophos
Methapyrilene
Methfuroxam
Methidathion
Methomyl except when included in Schedule 6.
Methyl Bromide
Mevinphos
Mipafox
Mirex
Monocrotophos
Naphthalophos except when included in Schedule 6.
Nicotine except:
(a)when included in Schedule 4 or 6;
(b)in tobacco.
Nimidane except when included in Schedule 6.
Nitrofen
Omethoate except when included in Schedule 6.
Oxamyl
Oxyfluorfen
Paraquat except when included in Schedule 6.
Parathion
Parathion-methyl
Phenkapton except when included in Schedule 6.
Phorate
Phosfolan
Phosphamidon
Polychlorinated Biphenyls
Promecarb except when included in Schedule 6.
Schradan
Strychnine except:
(a)Nux vomica included in Schedule 1; or
(b)when included in Schedule 4 or 6.
Sulfallate
Sulfotep
Sulphatroxazole, except when included in Schedule 4.
TEPP
Terbufos
Tetrachloroethane
Thallium
Thiofanox
ortho-Tolidine except when included in Schedule 6 and in solid-state diagnostic therapeutic reagents.
Triamiphos
Triazbutil
Trichloroisocyanuric Acid except:
(a)in preparations containing 4 per cent or less of available chlorine; or
(b)when included in Schedule 5.
Vinyl Chloride
SCHEDULE 8 Section 3
Acetyldihydrocodeine except when included in Schedule 2 or 4.
Acetylmethadol
Acetylmorphines
Alfentanil
Allylprodine
Alphacetylmethadol
Alphameprodine
Alphamethadol
Alphaprodine
Amphetamine
Amylobarbitone except when included in Schedule 4.
Anileridine
Benzethidine
Benzylmorphine
Betacetylmethadol
Betameprodine
Betamethadol
Betaprodine
Bezitramide
Butobarbitone
Clonitazene
Cocaine and any solution or dilution in an inert substance whether liquid or solid in any proportion and all preparations and admixtures.
Coca Leaf
Codeine except when included in Schedule 2, 3 or 4.
Codeine-N-oxide
Codoxime
Concentrate of Poppy Straw (the material arising when poppy straw has entered into a process for concentration of its alkaloids).
4-Cyano-2-dimethylamino-4-4-diphenylbutane (Moramide intermediate).
4-Cyano-1-methyl-4-phenylpiperidine (Pethidine intermediate A).
Cyclobarbitone
Dexamphetamine
Dextromoramide
Dextropropoxyphene except when included in Schedule 4.
Diampromide
Diethylthiambutene
Difenoxin except when included in Schedule 4.
Dihydrocodeine except when included in Schedule 2 or 4.
Dihydromorphine
Dimenoxadol
Dimepheptanol
Dimethylthiambutene
Dioxaphetyl Butyrate
Diphenoxylate except when included in Schedule 4.
Dipipanone
Drotebanol
Ecgonine
Ethylmethylthiambutene
Ethylmorphine except when included in Schedule 2 or 4.
Etonitazene
Etoxeridine
Fentanyl
Furethidine
Hydrocodone
Hydromorphinol
Hydromorphone
Hydroxypethidine
Isomethadone
Levomethorphan
Levomoramide
Levophenacylmorphan
Levorphanol
Mecloqualone
Metazocine
Methadone
Methaqualone
Methylamphetamine
Methyldesorphine
Methyldihydromorphine
2-Methyl-3-morpholino-1-1-diphenyl Propane Carboxylic Acid (Methadone intermediate)
Methylphenidate
1-Methyl-4-phenylpiperidine-4-carboxylic Acid (Pethidine intermediate C)
Metopon
Morpheridine
Morphine
Morphine Methobromide
Morphine-N-oxide
Myrophine
Nabilone
Nicocodine except when included in Schedule 2 or 4.
Nicodicodine except when included in Schedule 2 or 4.
Nicomorphine
Noracymethadol
Norcodeine except when included in Schedule 2 or 4.
Norlevorphanol
Normethadone
Normorphine
Norpipanone
Opium in any form except the alkaloids noscapine and papaverine.
Oxycodone
Oxymorphone
Pentazocine
Pentobarbitone except when included in Schedule 4.
Pethidine
Phenadoxone
Phenampromide
Phenazocine
Phencyclidine
Phenmetrazine
Phenomorphan
Phenoperidine
4-Phenylpiperidine-4-carboxylic Acid Ethyl Ester (Pethidine intermediate B)
Pholcodine except when included in Schedule 2 or 4.
Piminodine
Piritramide
Proheptazine
Properidine
Propiram
Quinalbarbitone
Racemethorphan
Racemoramide
Racemorphan
Secbutobarbitone
Sufentanil
Thebacon
Thebaine
Tilidine
Trimeperidine
NOTES
Notified in the Commonwealth of Australia Gazette on 31 July 1986.
No. 38, 1978 as amended by Nos. 19 and 56, 1981; No. 47, 1982; No. 67, 1985.
0
0
0